Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateSector Deep DivesUploadPipelinePE CyclesBrainAboutHow We Research

Data updated weekly. Not financial advice.

sectoralpha · stock story
Pharma - Formulators →
Home›Stocks›Rubicon Research Ltd
RUBICONRubicon Research LtdPharma - Formulators
₹1,368

Rubicon Research Ltd (RUBICON) — share price & stock analysis

From losses in FY22 and FY23 to record profits — the comeback is real, the price knows it.

TURNAROUND
STAGE 2 UPTREND
TURNAROUNDMARGINS EXPANDINGLOW DEBT
DEEP CYCLICALEXPANSION
₹22,628 Cr
Market cap
91.7×
P/E
27.0%
ROE
By Sector Alpha Research · machine-compiled from Screener.in data · Updated 1 July 2026 · Sources: Screener.in company page, NSE quote · Not investment advice
The 30-second answer

Rubicon Research Ltd (RUBICON) trades at ₹1,368 as of 1 July 2026. The machine reads this as turnaround: from losses in FY22 and FY23 to record profits — the comeback is real, the price knows it. the price is in Stage 2 — advancing, 29 weeks in; the business cycle reads DEEP CYCLICAL / EXPANSION. Fundamentals-momentum score: 100/100 (all improving).

Data as of 1 July 2026 · every number traces to its Screener source column · not investment advice.

Key numbers
Market cap
₹22,628 Cr
P/E
91.7×
ROE
27.0%
Book value / share
₹78.1
Revenue (FY26)
₹1,754 Cr
Profit after tax (FY26)
₹247 Cr
Weinstein stage
Stage 2 (29 weeks)
Data as of
1 July 2026
MOMENTUM OF THE FUNDAMENTALS
100/100
ALL IMPROVING
Levels: ROCE 28% — a high-quality engine · effectively no debt · margins near the top of their band
SalesUp 44% YoY
MarginsOPM 20.2% → 23.1% in a year
ProfitUp 114% YoY
Cash generationOperating cash ₹159 Cr → ₹205 Cr
Balance sheetDebt is ₹24 per ₹100 of shareholders’ money
DEEP CYCLICAL
Trough
Recovery
Expansion
Peak

Profits swing violently in this business — real losses in FY22 and FY23. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.net_profit

Where the clock stands now: earnings sit at 100% of their historical range, margins are near the top of their band, and valuation history is thin. That reads as EXPANSION — the comfortable middle — but the records are already on the table; from here the bet is that they keep coming.net_profit

5 of the 5 things we track are currently moving the right way — nearly everything is pulling in the same direction.

Where the levels actually stand: ROCE 28% — a high-quality engine; effectively no debt; margins near the top of their band. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double.

WHERE THE PRICE IS IN ITS CYCLE

The price is in a confirmed uptrend — 29 weeks and counting

STAGE 2 · ADVANCING · 29 WEEKS

Stock prices move through four repeating stages: basing (1), advancing (2), topping (3) and declining (4). This one is in Stage 2: advancing, 29 weeks in, confirmed.stage

The price sits above its rising 200-day average (₹872 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

Weekly price with its 200-day and 50-day averages — stages shaded₹weinstein_stages
S1S27501,0001,250Price200-DMAStage 2 began · Jan 26Oct 25Feb 26May 26Jul 26
Data: Weekly price, moving averages and stage
PeriodPrice (₹)200-DMA (₹)50-DMA (₹)Stage
Oct 256196286284
Oct 255776276234
Oct 256186266214
Nov 256276276244
Nov 257146286281
Nov 256786326421
Nov 256566336451
Dec 256366336431
Dec 256366336411
Dec 256566336411
Dec 256826356471
Jan 266616376512
Jan 266516386552
Jan 266766406582
Jan 266506416582
Feb 266796436612
Feb 267856486782
Feb 267856556972
Feb 267806617142
Feb 267806677262
Mar 267666717322
Mar 267696767412
Mar 267836807452
Mar 267686847492
Apr 267756877522
Apr 268366937632
Apr 268996997762
Apr 269397108042
Apr 269707208282
May 269567338542
May 269617438712
May 269507548902
May 261,0067639032
Jun 261,2987839562
Jun 261,2037879662
Jun 261,1717959822
Jun 261,1887989902
Jun 261,2968081,0132
Jun 261,3688241,0522
Jun 261,3628341,0732
Jun 261,3928511,1092
Jun 261,4178561,1212
Jul 261,3688721,1522
THE LONG ARC

From losing money in FY22 and FY23 to record profits

Over 6 years, sales went from ₹263 Cr to ₹1,754 Cr (about 37% a year), and profit from ₹49.0 Cr to ₹247 Cr.revenuenet_profit

The books show real losses in FY22 and FY23 (worst: ₹−67.0 Cr). Everything about today’s cheap-looking numbers must be read against that history — the recovery is what you are buying.net_profit

Revenue by year₹ Crannual_results
01,000FY20FY23FY26
Data: Revenue by year
PeriodRevenue (₹ Cr)
FY20263
FY21315
FY22314
FY23394
FY24854
FY251,284
FY261,754
Profit by year₹ Crannual_results
0200FY20FY23FY26
Data: Profit by year
PeriodProfit after tax (₹ Cr)
FY2049
FY2131
FY22-67
FY23-17
FY2491
FY25134
FY26247
OPM % by year%annual_results
0.020.0FY20FY23FY26
Data: OPM % by year
PeriodOPM % (%)
FY2030.8
FY2129.2
FY22-12.4
FY234.6
FY2418.1
FY2519.9
FY2622.8
CHAPTER 1 · THE ENGINE

Sales exploded 44% last quarter

Revenue — the money that comes in from customers, before any costs.

Mar 26 sales were ₹514 Cr, up 44% on the same quarter last year.revenue

Quarterly sales₹ Crquarterly_results
0200400YoY %+39+52+44Sep 24Jun 25Mar 26
Data: Quarterly sales
PeriodRevenue (₹ Cr)YoY growth (%)
Sep 24296–
Dec 24313–
Mar 25358–
Jun 25352–
Sep 2541239.2
Dec 2547652.1
Mar 2651443.6
WATCH →If quarterly growth slips below 22%, the story weakens.
CHAPTER 2 · THE TAKE

Margins are widening — 20% → 23% in a year

Margins — the share of every ₹100 of sales kept as profit. Gross (after raw materials), operating (after running costs), net (after everything).

Of every ₹100 of sales, the company keeps ₹23.1 as operating profit (a year ago it kept ₹20.2).opm_pct

Zoom out and this is the page's quiet hero: annual operating margin bottomed at −12.4% in FY22 and has been rebuilt to 22.8% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit

The gross margin barely moved (69% → 67%), so the change came from running costs — the business is getting more efficient as it scales.gpm_pctopm_pct

Three margins, quarterly%margin_trends
20.040.060.0GrossOperatingNetSep 24Jun 25Mar 26
Data: Three margins, quarterly
PeriodGross (%)Operating (%)Net (%)
Sep 2473.320.811.7
Dec 2468.522.312.2
Mar 2568.820.210.1
Jun 2570.822.512.3
Sep 2569.322.913.1
Dec 2566.922.715.3
Mar 2667.123.114.9
WATCH →Two consecutive quarters of margin decline would break this trend.
CHAPTER 3 · THE BOTTOM LINE

Profit exploded 114% — mostly from selling more

PAT (profit after tax) — what is left for shareholders after every cost, interest and tax.

Mar 26 profit after tax was ₹77.0 Cr, up 114% year on year.net_profit

Quarterly profit after tax₹ Crquarterly_results
025.050.075.0YoY %+59+92+114Sep 24Jun 25Mar 26
Data: Quarterly profit after tax
PeriodPAT (₹ Cr)YoY growth (%)
Sep 2434.0–
Dec 2438.0–
Mar 2536.0–
Jun 2543.0–
Sep 2554.058.8
Dec 2573.092.1
Mar 2677.0113.9
Where the profit change came from (Mar 25 → Mar 26)₹ Cr
36+31+16+3−2+2−7−277PAT Mar 25More salesFattermarginsOther incomeDepreciationInterestTaxEverythingelsePAT Mar 26

The single biggest driver was selling more.

Data: Where the profit change came from (Mar 25 → Mar 26)
ComponentEffect (₹ Cr)
PAT Mar 2536
More sales+31
Fatter margins+16
Other income+3
Depreciation−2
Interest+2
Tax−7
Everything else−2
PAT Mar 2677
CHAPTER 4 · THE ACID TEST

Most of the profit becomes cash — but not all

Operating cash flow (CFO) — the cash that actually arrived, vs PAT, the profit accounting reports. Annual figures.

Over the last 3 profitable years, the business reported ₹472 Cr of profit and collected ₹385 Cr of operating cash — about 82% conversion (2 loss years excluded — a negative denominator would flatter the ratio).operating_cash_flownet_profit

The gap sits in receivables: customers now take 106 days to pay, up from 92. Profit booked, cash pending.debtor_days

Cash collected vs profit reported (annual)₹ Crcash_flow
-1000100200Operating cash flowProfit after taxFY20FY23FY26
Data: Cash collected vs profit reported (annual)
PeriodOperating cash flow (₹ Cr)Profit after tax (₹ Cr)
FY205.049.0
FY2162.031.0
FY22-63.0-67.0
FY23-75.0-17.0
FY2421.091.0
FY25159134
FY26205247
CHAPTER 5 · THE PIPELINE

The cash cycle is tightening — money comes home faster

Working capital — days of sales locked up in inventory and unpaid bills. Screener reports this yearly, so this chart is annual.

One rupee now takes about 337 days to go out the door as materials and come back as collected cash — down from 403 days the year before.cash_conversion_cycle

The biggest mover: inventory moving faster off the shelf (574 → 479 days).inventory_days

Days of cash locked up (annual)daysratios
200400600Customers owe (debtor days)Stock on shelf (inventory days)We owe suppliers (payable days)FY20FY23FY26
Data: Days of cash locked up (annual)
PeriodCustomers owe (debtor days) (days)Stock on shelf (inventory days) (days)We owe suppliers (payable days) (days)
FY20194360183
FY21158508271
FY22162502320
FY23209609353
FY24129428252
FY2592.0574263
FY26106479248
CHAPTER 6 · THE BUILD

The asset base keeps compounding — this company builds

Capex — money spent on plants, machines and buildings. Gross block is what exists; CWIP (capital work-in-progress) is what is being built. Annual.

The productive asset base has gone from ₹157 Cr (FY20) to ₹532 Cr, with another ₹40.0 Cr of capacity under construction right now.fixed_assetscwip

The build is bigger than the cash engine: investing outflows (₹543 Cr) exceeded operating cash (₹385 Cr) over the last 3 years — the difference comes from debt or shareholders.investing_cash_flowoperating_cash_flow

Assets in place vs under construction (annual)₹ Crbalance_sheet
0200400Fixed assetsUnder construction (CWIP)FY20FY23FY26
Data: Assets in place vs under construction (annual)
PeriodFixed assets (₹ Cr)Under construction (CWIP) (₹ Cr)
FY201572.0
FY211886.0
FY221933.0
FY2319925.0
FY2430710.0
FY253277.0
FY2653240.0
CHAPTER 7 · SURVIVAL

Debt is small — but no longer zero, and growing

Debt-to-equity — borrowings against shareholders’ money. Computed from the balance sheet. Annual.

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹24 — total borrowings have grown from ₹30.0 Cr to ₹311 Cr over the window.borrowings

The equity base grew even faster, so the ratio stays comfortable — but a 10× rise in absolute borrowings deserves a name (acquisitions, capex), not a shrug. Watch whether it keeps compounding.borrowings

Total borrowings (annual)₹ Crbalance_sheet
0200400FY20FY23FY26
Data: Total borrowings (annual)
PeriodBorrowings (₹ Cr)
FY2030.0
FY2193.0
FY22175
FY23320
FY24425
FY25418
FY26311
Debt vs shareholders’ money (annual)xbalance_sheet
00.51FY20FY23FY26
Data: Debt vs shareholders’ money (annual)
PeriodDebt ÷ equity (x)
FY200.1
FY210.3
FY220.6
FY231.1
FY241.1
FY250.8
FY260.2
CHAPTER 8 · THE ENGINE ROOM

Every ₹100 kept in the business now earns ₹28 — and the number is rising

ROCE — profit earned per ₹100 of capital used. ROE — the same, per ₹100 of shareholders’ money alone. Annual.

Return on capital employed is 28.0% (a year ago: 26.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct

Returns on capital (annual)%ratios
0.020.0ROCEFY21FY23FY25FY26
Data: Returns on capital (annual)
PeriodROCE (%)
FY2117.0
FY22-12.0
FY231.0
FY2419.0
FY2526.0
FY2628.0
THE VERDICT

Worth studying deeper — with eyes open

The numbers lean positive, and the price is roughly fair to the delivery so far.

Best thing in the data: profit rising (₹36.0 Cr → ₹77.0 Cr).net_profit

Biggest worry: free cash flow falling (₹94.0 Cr → ₹−205 Cr).operating_cash_flow

One dissent worth hearing: our catalysts lens reads negative — “4 earnings trigger(s): Pithampur Capacity Unlock — Gross Margin Recovery, R&D Pipeline Commercialization — 24 Products Under FDA Review, Specialty Portfolio Mix”. When a lens disagrees with the committee, it is usually pointing at the thing that breaks first.

The machine committee — 7 independent readsSTUDY DEEPER · 76%
Earnings patternPOSITIVE100% · w21
Valuation cyclePOSITIVE70% · w19
CatalystsNEGATIVE60% · w14
Quality & safetyPOSITIVE58% · w14
TechnicalsPOSITIVE40% · w12
ValuationNEGATIVE80% · w10
Growth at a pricePOSITIVE52% · w10
One model disagrees — the Catalysts lens reads this stock as NEGATIVE (60% confidence): “4 earnings trigger(s): Pithampur Capacity Unlock — Gross Margin Recovery, R&D Pipeline Commercialization — 24 Products Under FDA Review, Specialty Portfolio Mix”
Business quality7.2/10
Management6.5/10
7-model research readSTUDY DEEPER · 76% confidence
WHAT WOULD CHANGE THIS VIEWTwo quarters of margins reversing would kill this story.

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

More Pharma - Formulators stocks
Sun Pharmaceutical Industries LtdTorrent Pharmaceuticals LtdCipla LtdDr Reddys Laboratories LtdZydus Lifesciences LtdLupin LtdAll Pharma - Formulators stocks →
Frequently asked questions

Straight answers from the data

What does Rubicon Research Ltd do?

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]. It is listed in the Pharma - Formulators sector with a market capitalisation of ₹22,628 Cr.

What is Rubicon Research Ltd's share price?

As of 1 July 2026, Rubicon Research Ltd trades at ₹1,368, with a market capitalisation of ₹22,628 Cr. Prices are weekly closes from Screener data; this page refreshes with each weekly update.

What is Rubicon Research Ltd's share price target?

Sector Alpha does not publish broker-style price targets. Our discounted-cash-flow model estimates Rubicon Research Ltd's intrinsic value at ₹994 per share under base assumptions (bear ₹280, bull ₹994), against the current price of ₹1,368 — a 16% premium to model value. These are model estimates, not forecasts — treat them as one input alongside the valuation history below, not as a target.

What did Rubicon Research Ltd report in its latest quarterly results?

In its most recent reported quarter (Q4 FY26, quarter ended March 2026): Mar 26 sales were ₹514 Cr, up 44% on the same quarter last year. Mar 26 profit after tax was ₹77.0 Cr, up 114% year on year. Figures are from Screener-scraped quarterly filings; the page updates when the next quarter is filed.

Is Rubicon Research Ltd growing?

Sales exploded 44% last quarter. Mar 26 sales were ₹514 Cr, up 44% on the same quarter last year.

Are Rubicon Research Ltd's profits growing?

Profit exploded 114% — mostly from selling more. Mar 26 profit after tax was ₹77.0 Cr, up 114% year on year.

What are Rubicon Research Ltd's operating margins?

Margins are widening — 20% → 23% in a year. In the most recent quarter, of every ₹100 of sales, the company keeps ₹23.1 as operating profit (a year ago it kept ₹20.2).

What is Rubicon Research Ltd's long-term growth record?

Revenue grew from ₹263 Cr in FY20 to ₹1,754 Cr in FY26 — a 37.2% compound annual growth rate over 6 years. Profit after tax compounded at 30.9% over the same period (₹49 Cr → ₹247 Cr).

Is Rubicon Research Ltd stock in an uptrend?

The price is in a confirmed uptrend — 29 weeks and counting. Rubicon Research Ltd is in Stage 2 — advancing, 29 weeks in (confirmed). Stages follow Stan Weinstein's four-phase read of weekly price against the 200-day average: basing (1), advancing (2), topping (3), declining (4).

Where is Rubicon Research Ltd in its business cycle?

The data reads Rubicon Research Ltd as a deep cyclical business currently in its expansion phase — earnings at an all-time high for this company. Profits swing violently in this business — real losses in FY22 and FY23. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.

Does Rubicon Research Ltd have too much debt?

Debt is small — but no longer zero, and growing. For every ₹100 shareholders have put in (and left in), the company has borrowed ₹24 — total borrowings have grown from ₹30.0 Cr to ₹311 Cr over the window.

What is the bull case for Rubicon Research Ltd?

From losses in FY22 and FY23 to record profits — the comeback is real, the price knows it. Best thing in the data: profit rising (₹36.0 Cr → ₹77.0 Cr). Sales exploded 44% last quarter.

What is the bear case for Rubicon Research Ltd — what could break the story?

Biggest worry: free cash flow falling (₹94.0 Cr → ₹−205 Cr). Two quarters of margins reversing would kill this story. The nearest-term thing to watch: if quarterly growth slips below 22%, the story weakens. This falsification condition is stated up front so the thesis can be checked against incoming quarters, not defended after the fact.

Is Rubicon Research Ltd a stock worth studying right now?

Sector Alpha does not publish buy or sell recommendations — this is a research read, not advice. What the data says: worth studying deeper — with eyes open. The numbers lean positive, and the price is roughly fair to the delivery so far. Across the 7-model scorecard the composite research signal is study deeper at 76% confidence. This is machine-written research compiled from Screener data — every number traces to its source — and it is not investment advice. Do your own diligence.

Generated from Screener data · 12 sources · why_traces/1.0 + story/1.2
details
generated 2026-07-03 11:21 · 8 material moves detected
sources: screener_company_info, screener_quarterly_results, screener_annual_results, screener_valuation_history, screener_shareholding, screener_cash_flow, screener_ratios, screener_balance_sheet, screener_margin_trends, weinstein_stages, agent_scores, stock_timelines